New in-vitro diagnostics and therapeutics are needed to monitor, predict and treat metastatic cancer. This would help stratify patients for optimal treatment and follow-up care. We are developing cancer diagnostics that will give clinicians the power to detect and predict metastasis and the metastatic therapeutic to then block the spread. With these tests and treatment we will redefine the cancer care pathway. We were awarded £210K in non-diluting funding and are looking for investors and partners to join us on this exciting journey.